{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:19:17Z","timestamp":1787761157971,"version":"build-2784847793"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Several chimeric antigen receptor T-cell constructs (CAR-T cells) are currently approved for the treatment of B-cell malignancies, including non-Hodgkin lymphoma and acute lymphoblastic leukemia. Additionally, multiple other products are being investigated and developed for other hematological malignancies and solid cancers. Patients receiving CAR-T cells are at increased risk of infectious complications that lead to increased morbidity and inferior mortality in these patients. In this review, we discuss the literature on the incidence and types of infection in patients in the early and late-phase after CAR-T cells infusion. Additionally, we summarize the current literature on prophylaxis against viral, bacterial, and fungal infections after CAR-T cells infusion and the utility of preventative and supportive measures including intravenous immunoglobulins and myeloid growth factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.56875\/2589-0646.1049","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T05:28:20Z","timestamp":1671686900000},"page":"153-158","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Infectious Complications and Preventative Strategies following Chimeric Antigen Receptor T-cells (CAR-T cells) Therapy for B-Cell Malignancies"],"prefix":"10.4103","volume":"15","author":[{"given":"Alfadil","family":"Haroon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim N.","family":"Muhsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad B.","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulwahab","family":"Albabtain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alahmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed O.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad E.","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20241211","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR-Therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"R2-11-20241211","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR-T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-11-20241211","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"R4-11-20241211","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jha2.340","article-title":"Chimeric antigen receptor-T cell therapies: the changing landscape","volume":"3","author":"Sengsayadeth","year":"2021","journal-title":"eJHaem"},{"key":"R5-11-20241211","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"R6-11-20241211","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jtct.2020.10.002","article-title":"Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Transplantation and Cellular Therapy"},{"key":"R7-11-20241211","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood.2022015728","article-title":"Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IEs","volume":"140","author":"Steffin","year":"2022","journal-title":"Blood"},{"key":"R8-11-20241211","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy\u2013associated cardiomyopathy in patients with refractory or relapsed non- hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"R9-11-20241211","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/hon.2957","article-title":"SARS-CoV-2 vaccine response in CAR T-cell therapy recipients: a systematic review and preliminary observations","volume":"40","author":"Abid","year":"2022","journal-title":"Hematol Oncol"},{"key":"R10-11-20241211","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","article-title":"Poor outcome of patients with COVID-19 after CAR T-cell therapy for B- cell malignancies: results of a multicenter study on behalf of the European society for blood and marrow transplantation (EBMT) infectious diseases working party and the European hematology association (EHA) lymphoma group","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"key":"R11-11-20241211","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtct.2021.09.016","article-title":"State of the CAR-T: risk of infections with chimeric antigen receptor T-cell therapy and determinants of SARS-CoV-2 vaccine responses","volume":"27","author":"Meir","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R12-11-20241211","doi-asserted-by":"crossref","first-page":"204993612110367","DOI":"10.1177\/20499361211036773","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Therapeutic Advances in Infectious Disease"},{"key":"R13-11-20241211","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"R14-11-20241211","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S1470-2045(21)00695-1","article-title":"Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era","volume":"23","author":"Abid","year":"2022","journal-title":"Lancet Oncol"},{"key":"R15-11-20241211","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Advances"},{"key":"R17-11-20241211","doi-asserted-by":"crossref","first-page":"e26914","DOI":"10.1002\/pbc.26914","article-title":"Hypogammaglobulinemia due to CAR T-cell therapy","volume":"65","author":"Doan","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R18-11-20241211","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-141224","article-title":"Hypogammaglobulinemia and infection risk in chronic lymphocytic leukemia (CLL) patients treated with CD19- directed chimeric antigen receptor T (CAR-T) cells","volume":"136","author":"Uy","year":"2020","journal-title":"Blood"},{"key":"R19-11-20241211","doi-asserted-by":"crossref","first-page":"AB1","DOI":"10.1016\/j.jaci.2020.12.054","article-title":"Significant hypogammaglobulinemia in patients receiving CAR T-cell therapy","volume":"147","author":"Barmettler","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R21-11-20241211","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1080\/10428194.2021.1881506","article-title":"Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells","volume":"62","author":"Wittmann Dayagi","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"R22-11-20241211","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1182\/bloodadvances.2022007474","article-title":"Low incidence of invasive fungal disease following CD19 chimeric antigen receptor Tcell (CAR-T) therapy for non-hodgkin lymphoma","volume":"6","author":"Little","year":"2022","journal-title":"Blood Adv"},{"key":"R23-11-20241211","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"R24-11-20241211","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"key":"R25-11-20241211","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QCO.0000000000000679","article-title":"Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties","volume":"33","author":"Haidar","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"R26-11-20241211","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Longterm safety and activity of axi- cabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"R27-11-20241211","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-hodgkin lymphoma: an expert panel opinion from the American society for transplantation and cellular therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R30-11-20241211","doi-asserted-by":"crossref","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T - and a side order of IgG, to go? - immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"key":"R31-11-20241211","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1200\/JCO.21.02694","article-title":"Granulocyte colony-stimulating factor usage in recipients of chimeric antigen receptor T-cell immunotherapy","volume":"40","author":"Abid","year":"2022","journal-title":"J Clin Oncol"},{"key":"R33-11-20241211","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41409-021-01526-0","article-title":"Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma","volume":"57","author":"Li\u00e9vin","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"R34-11-20241211","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/ijc.33356","article-title":"Filgrastim associations with CAR T-cell therapy","volume":"148","author":"Gaut","year":"2021","journal-title":"Int J Cancer"},{"key":"R35-11-20241211","doi-asserted-by":"crossref","first-page":"E399","DOI":"10.1002\/ajh.26313","article-title":"The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy","volume":"96","author":"Barreto","year":"2021","journal-title":"Am J Hematol"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.56875\/2589-0646.1049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:25:24Z","timestamp":1787757924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.56875\/2589-0646.1049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.56875\/2589-0646.1049","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}